Perrigo OK’D on Generic Loprox

U.S. firm Perrigo said Tuesday it has been approved for U.S. sales of a generic version of Medicis’ anti-fungal drug Loprox.

The company said the Food and Drug Administration cleared marketing of ciclopirox topical suspension, 0.77-percent lotion to treat common skin infections, including athlete’s foot, jock itch and ringworm.

Perrigo estimated U.S. sales of Loprox for the last 12 months at about $42 million, quoting data from Wolters Kluwer.

Medicis announced earlier this year it was issued two U.S. patents relating to another product in the Loprox line, Loprox Gel, 0.77 percent, used to treat dermatomycoses such as tinea pedis and tinea corporis. The company said it has other patents pending for other forms of Loprox.